Cartalax
Also known as: Ala-Glu-Asp, AED Tripeptide
Key Facts: Cartalax
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Available in Russia - Not FDA approved
- Administration
- Oral
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Evidence Level
- Animal Studies
- Duration
- 10-30 day courses
What to Expect
A synthetic tripeptide bioregulator targeting cartilage tissue. Developed for joint health and cartilage regeneration.
Mechanism of Action
Cartalax regulates gene expression in chondrocytes and cartilage tissue. It promotes cartilage matrix protein synthesis and may support joint health through bioregulatory effects.
Research Summary
Russian research shows cartilage protective effects and improved joint function. Studies demonstrate increased glycosaminoglycan and collagen synthesis. Limited Western validation.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Doses from Russian protocols
Doses from Studies
10-20 mg daily
Oral capsules
Duration
10-30 day courses
Administration
Oral
Timing & Administration
Best Time to Take
Morning or as directed
Follow recommended protocol
Food Recommendation
With or without food
Why This Timing?
Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Mild injection site reactions
- ●Transient fatigue
- ●Mild GI upset (rare)
- ●Limited documented side effect data
References
Related Peptides
Peptides commonly compared with Cartalax or used in similar applications.
Epithalon
Clinical TrialsA tetrapeptide studied for its effects on telomerase activation and potential anti-aging properties. Based on research by Professor Vladimir Khavinson.
BioregulatorsThymalin
Clinical TrialsA thymic peptide complex used in Russia for immune enhancement and anti-aging. Part of Professor Khavinson's bioregulator peptide research.
BioregulatorsPinealon
PreclinicalA synthetic tripeptide bioregulator targeting brain tissue. Part of Khavinson's peptide research, designed to support cognitive function and neuroprotection.
BioregulatorsVilon
PreclinicalA synthetic dipeptide bioregulator targeting thymic function. Part of Khavinson's peptide bioregulator research for immune and anti-aging effects.
BioregulatorsLivagen
PreclinicalA tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Khavinson that modulates chromatin structure and gene expression. Research shows it can decondense heterochromatin and activate ribosomal genes, potentially restoring more youthful gene expression patterns in aging cells.
BioregulatorsOvagen
PreclinicalA tripeptide bioregulator (Glu-Asp-Leu) targeting liver and gastrointestinal tissue. Derived from liver tissue extracts, Ovagen modulates gene expression related to detoxification, antioxidant defense, and hepatocellular repair.
BioregulatorsWant updates on Cartalax research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.